Histomorphological analysis of preservation injury as determinant of graft quality in clinical liver transplantation

Administration of granulocyte colony stimulating factor after liver transplantation leads to an increased incidence and severity of ischemic biliary lesions in the rat model

AIM: Recently it has been reported that granulocyte colony stimulating factor (G-CSF) can induce hypercoagulability in healthy bone marrow donors. It is conceivable that the induction of a prothrombotic state in a recipient of an organ graft with already impaired perfusion might cause further deterioration in the transplanted organ. This study evaluated whether G-CSF treatment worsens liver perfusion following liver transplantation in the rat model.

METHODS: A non-arterialized rat liver transplantation model was employed to evaluate the effect of G-CSF treatment on the liver in a syngeneic and allogeneic strain combination. Study outcomes included survival time and liver damage as investigated by liver enzymes and liver histology. Observation times were 1 d, 1 wk and 12 wk.

RESULTS: Rats treated with G-CSF had increased incidence and severity of biliary damage following liver transplantation. In these animals, hepatocellular necrosis was accentuated in the centrilobular region. These lesions are indicative of impaired perfusion in G-CSF treated animals.

CONCLUSION: G-CSF should be used with caution in recipients of liver transplantation, as treatment might enhance preexisting, undetected perfusion problems and ultimately lead to ischemia induced biliary complications.

Characterization of hepatic parenchymous perfusion heterogeneity and regional flow kinetics after porcine liver transplantation

BACKGROUND

In clinical practice, a heterogeneous hepatic tissue microperfusion (MC) is often observed after liver resection or transplantation (LTx). Nevertheless this hepatic perfusion phenomenon has never been really quantified with respect to its anatomic distribution and time course in detail. The aim of the study was to characterize liver perfusion heterogeneity and local flow kinetics both in the physiological situation and after standardized ischemia and reperfusion using an established model of porcine LTx.

METHODS

Regional distribution of hepatic MC in healthy native porcine livers (control group; n = 8) was analyzed in comparison with data derived 60 min, 24 h, and 72 h after porcine LTx (transplantation group; n = 8 each subgroup; cold ischemia time: 5.7 +/- 1.2 h). MC was measured with implanted thermal diffusion electrodes (TD). Flow in hepatic artery and portal vein was continuously detected by ultrasonic probes. For standardization of measurement localizations, porcine liver lobes were divided anatomically into three horizontal layers (cranial, medial, caudal), defining 12 distinct hepatic measurement regions.

RESULTS

In the control group, a homogenous liver MC with a mean flow of 81.6 +/- 13.9 ml/100 g/min was detected in all regions. After LTx, a marked MC heterogeneity was noted 60 min after reperfusion. MC rehomogenization was first documented within horizontal liver planes 24 h later. Comparison of MC between planes showed persisting heterogeneity with a significant intralober drop of mean MC in the cranio-caudal direction. Complete MC rehomogenization (both between horizontal and vertical liver planes) was detected 72 h after reperfusion. Still, an overall reduction of mean liver perfusion by about 15% was existent.

CONCLUSIONS

A homogenous tissue perfusion was observed in healthy porcine livers. In contrast, marked heterogeneity of hepatic MC was detected after LTx. Heterogeneity presents as a very dynamic and temporary phenomenon. Early horizontal flow rehomogenization and reconstitution of normal blood flow, particularly primarily in the cranial liver layers, appear to be characteristic features during early flow reconstitution after postischemic reperfusion. Due to heterogeneity and time-dependent flow dynamics, measurement of MC volumes at single hepatic regions may not always allow a valid characterization of liver perfusion quality during the first 24 h after postischemic reperfusion.

N-acetilcisteína diminui a congestão hepática na lesão de isquemia e reperfusão: estudo experimental

OBJETIVOS: A isquemia tem sido utilizada na cirurgia hepática desde o início do século. Embora possibilite a diminuição da perda sangüínea durante as ressecções e a manutenção do órgão à espera de um transplante, a ausência de perfusão traz como conseqüência um dano ao órgão, que se amplifica por ocasião da sua reoxigenação. A N-Acetilcisteína é uma droga capaz de repor os estoques celulares de glutationa, um antioxidante fundamental no controle das lesões resultantes do restabelecimento da perfusão sangüínea, esperando-se dessa forma que diminua a lesão acima descrita. Com o propósito de avaliar a capacidade da N-Acetilcisteína reduzir o dano hepático, utilizou-se um modelo murino de isquemia e reperfusão normotérmica. MÉTODO: Foram utilizados vinte ratos Wistar fêmeas, divididos em dois grupos. No grupo tratado, 400mg/kg de N-Acetilcisteína foram administrados pela via intravenosa, 15 minutos antes do clampeamento do pedículo do lobo esquerdo por 90 minutos. No grupo controle foi administrado o volume equivalente de solução fisiológica. Foi estabelecido um período de quatro horas de reperfusão, após o qual os animais foram sacrificados para a realização de análise histopatológica do lobo esquerdo com coloração de Hematoxilina-Eosina. A lesão tecidual foi quantificada quanto à presença de congestão, esteatose e necrose. RESULTADOS: O estudo evidenciou a capacidade de a N-Acetilcisteína diminuir significativamente a congestão. Não houve diferenças quanto à presença de esteatose e necrose. CONCLUSÃO: Os resultados obtidos permitem-nos concluir que o uso prévio da N-Acetilcisteína nos processos de isquemia e reperfusão, em normotermia, é capaz de diminuir a congestão hepática. A N-Acetilcisteína não diminui a presença de esteatose e necrose.